Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF4 | P18848 | 16/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23294544 | 0.99 | ATF4 (0.69) | ATF4LMNARAB9AHPGDHTT | |
| SCHEMBL23702451 | 0.96 | ATF4 (0.66) | ATF4LMNARAB9AHPGDHTT | |
| Trifluoroacetic Acid SCHEMBL21819336 | 0.94 | ATF4 (0.63) | ATF4LMNARAB9AHPGDHTT | |
| SCHEMBL16082976 | 0.91 | ATF4 (0.78) | ATF4LMNARAB9AHPGDHTT | |
| SCHEMBL19692630 | 0.89 | ATF4 (0.59) | ATF4LMNARAB9AHPGDHTT | |
| SCHEMBL21384520 | 0.88 | ATF4 (0.67) | ATF4LMNA | |
| SCHEMBL19134205 | 0.88 | ATF4 (0.73) | ATF4LMNARAB9AHPGDNPC1 | |
| Hydrochloric Acid SCHEMBL19692616 | 0.88 | ATF4 (0.58) | ATF4LMNARAB9AHPGDHTT | |
| SCHEMBL22614154 | 0.87 | ATF4 (0.72) | ATF4LMNARAB9AHPGDHTT | |
| SCHEMBL21050157 | 0.87 | ATF4 (0.72) | ATF4LMNARAB9AHPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114980894-B | Modulators of integrated stress response pathways | 埃沃特克国际有限责任公司 | 2024-10-18 | — | — | CN | disclosed |
| US-20240140919-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | DENALI THERAPEUTICS INC. | 2024-05-02 | — | — | US | disclosed |
| US-20230250072-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | DENALI THERAPEUTICS INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230250072-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | DENALI THERAPEUTICS INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230250072-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | DENALI THERAPEUTICS INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230125481-A1 | MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY | EVOTEC INTERNATIONAL GMBH (DE) | 2023-04-27 | — | — | US | disclosed |
| US-20230125481-A1 | MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY | EVOTEC INTERNATIONAL GMBH (DE) | 2023-04-27 | — | — | US | disclosed |
| US-20230125481-A1 | MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY | EVOTEC INTERNATIONAL GMBH (DE) | 2023-04-27 | — | — | US | disclosed |
| EP-4096665-A1 | MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY | Evotec International GmbH (DE) | 2022-12-07 | — | — | EP | disclosed |
| CN-114980894-A | Modulators of integrated stress response pathways | 埃沃特克国际有限责任公司 | 2022-08-30 | — | — | CN | disclosed |
| US-11166942-B2 | Inhibitors of integrated stress response pathway | Praxis Biotech LLC (US) | 2021-11-09 | — | — | US | disclosed |
| WO-2021151865-A1 | MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY | EVOTEC INTERNATIONAL GMBH (DE) | 2021-08-05 | — | — | WO | disclosed |
| WO-2021151865-A1 | MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY | EVOTEC INTERNATIONAL GMBH (DE) | 2021-08-05 | — | — | WO | disclosed |
| US-20210130308-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | DENALI THERAPEUTICS INC. | 2021-05-06 | — | — | US | disclosed |
| US-20210130308-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | DENALI THERAPEUTICS INC. | 2021-05-06 | — | — | US | disclosed |
| EP-3768660-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | Denali Therapeutics Inc. (US) | 2021-01-27 | — | — | EP | disclosed |
| US-20200101047-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | Praxis Biotech LLC | 2020-04-02 | — | — | US | disclosed |
| WO-2019183589-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | DENALI THERAPEUTICS INC. (US) | 2019-09-26 | — | — | WO | disclosed |
| WO-2019183589-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | DENALI THERAPEUTICS INC. (US) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250072-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | EIF2A, EIF4A2, EIF4EBP1 | ATF4 118/4885LMNA 3077/4885RAB9A 1780/4885 |
| US-11166942-B2 | Inhibitors of integrated stress response pathway | ATF4, DDIT3, ATF1 | ATF4 1/4885LMNA 4459/4885RAB9A 3893/4885 |
| US-20210130308-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | EIF2A, EIF4A2, EIF4EBP1 | ATF4 118/4885LMNA 3077/4885RAB9A 1780/4885 |
| US-20200101047-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | ATF4, DDIT3, ATF1 | ATF4 1/4885LMNA 4459/4885RAB9A 3893/4885 |
| US-20230125481-A1 | MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY | CRHR2, CRHR1, CRH | ATF4 11/4885LMNA 2457/4885RAB9A 2381/4885 |
| US-20240140919-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | EIF2A, EIF4A2, EIF4EBP1 | ATF4 118/4885LMNA 3077/4885RAB9A 1780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.